Heim / Peptid-Wiki / Tirzepatide
Stoffwechsel

Tirzepatide

Dualer Agonist

FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound). Up to 22.5% weight loss in SURMOUNT-1 trial. Currently the most effective approved anti-obesity medication.

Aminosäuren39
Mol. Gewicht4813.5 Da
Halbwertszeitca. 5 Tage
Verfügbarkeit 🔔 Auf Anfrage
Aminosäuresequenz GIP/GLP-1 dual agonist

What Is Tirzepatide?

Tirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. FDA-approved as Mounjaro (T2D, 2022) and Zepbound (obesity, 2023). The SURMOUNT-1 trial demonstrated 22.5% body weight reduction at 72 weeks at 15mg — the highest for any approved pharmacological agent at the time.

Schlüsselmechanismen

  • GLP-1R agonism — appetite suppression and gastric emptying delay
  • GIPR agonism — synergistically amplifies GLP-1R-mediated weight loss; adipose tissue effects
  • Metabolic parameter improvement — HbA1c, triglycerides, blood pressure, HDL

Wichtige Referenzen

  1. Jastreboff AM et al. “Tirzepatide once weekly for the treatment of obesity.” N Engl J Med, 2022;387:205–216.
  2. Rosenstock J et al. “Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in T2DM.” Lancet, 2021;398:143–155.
🔬

Peptid anfordern

Füllen Sie das Formular aus, und wir melden uns innerhalb von 24 Stunden bei Ihnen.